ACAD stock: 100 shares | Yahoo -> Finance -> Conversation | My study

 March 29, 2021

I like to spend 10 to 15 minutes to read about ACAD stock since I did purchase 100 shares of ACAD at price of $28.15/ shares. 

Yahoo -> Finance -> Conversation

I am glad to have something to read. Compared to GRAY stock, I had over $8000 capital to invest on, there is nothing to read through Yahoo -> Finance. 

It is challenge for me to get updated on ACAD. I like to understand better after three to six months. 

• 2021 Guidance
  
  ACADIA expects total revenues from Nuplazid sales for the Parkinson’s disease psychosis indication to be in the range of $510-$550 million for 2021. The guidance does not include potential revenues from the dementia-related psychosis (“DRP”) indication, for which Nuplazid is currently under review.
  The company expects its R&D expenses to be in the range of $300-$320 million, while SG&A expenses are projected in the band of $560-$590 million for full-year 2021.
• 

  yesterday

  Question for the panel-----Is a CRL priced into the stock right now? If anything less than a CRL is revealed, like a 90 day extension for the company to provide any supplemental data or information requested by the FDA, does the price rebound back into the $40's? I am as baffled as everyone else here given the FDA's not only cooperation, but practically rolling out the red carpet for Nuplazid to be approved for DRP with all of the allowances they have provided ACAD. And the fact that the FDA even went through their own supplemental review of Nuplazid due to the hit piece 2 years ago and concluded, again, that there were no additional safety concerns over the drug and no anomalous adverse effects should have led to nothing but a smooth-sailing sNDA approval. As Ricky said to Lucy many times-----they have some splainin to do.

  

  How are you feeling about ACAD?

  Guidelines

  • 

    2 hours ago

    I guess the entire gamut has been covered. As annoying as it is, I think there will be a CRL, because the form letter is the standard precursor to a CRL. It seems unjust that the FDA would have waited this long after leading the company on. But, this is government and there's no accountability. Is the CRL baked in? We could figure that out only by knowing what's in the CRL. It's like someone telling you that they got in an automobile collision. What will it cost to repair? When will the car come out of the shop? And will it drive like it did before? There's a world of difference between a parking lot scratch from a shopping basket and a head on collision with a logging truck at 30 mph, but they are both accidents. So, I guess what's baked in is something in the middle.